These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 34030782)

  • 1. Idiopathic Thrombocytopenic Purpura and the Moderna Covid-19 Vaccine.
    Julian JA; Mathern DR; Fernando D
    Ann Emerg Med; 2021 Jun; 77(6):654-656. PubMed ID: 34030782
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune Thrombocytopenic Purpura (ITP) Triggered by COVID-19 Infection and Vaccination.
    David P; Dotan A; Mahroum N; Shoenfeld Y
    Isr Med Assoc J; 2021 Jun; 23(6):378-380. PubMed ID: 34155853
    [No Abstract]   [Full Text] [Related]  

  • 3. Immune thrombocytopenic purpura after SARS-CoV-2 vaccine.
    Candelli M; Rossi E; Valletta F; De Stefano V; Franceschi F
    Br J Haematol; 2021 Aug; 194(3):547-549. PubMed ID: 33934330
    [No Abstract]   [Full Text] [Related]  

  • 4. Immune thrombocytopenic purpura after vaccination with COVID-19 vaccine (ChAdOx1 nCov-19).
    Paulsen FO; Schaefers C; Langer F; Frenzel C; Wenzel U; Hengel FE; Bokemeyer C; Seidel C
    Blood; 2021 Sep; 138(11):996-999. PubMed ID: 34297792
    [No Abstract]   [Full Text] [Related]  

  • 5. Transplantation Outcome in Recipients Engrafted With Organs Recovered From the First French Deceased Donor With a SARS-COV-2 Vaccine-induced Thrombotic Thrombocytopenia.
    Jamme M; Elalamy I; d'Izarny Gargas T; Pettenati C; Desire E; Tissot A; Rabant M; Lefebvre M; Soorojebally Y; Vourc'h M; Conti F; Ferlicot S; Delahousse M; Sartorius-Brodin A; Hertig A
    Transplantation; 2021 Aug; 105(8):e84-e86. PubMed ID: 34115658
    [No Abstract]   [Full Text] [Related]  

  • 6. Successful mRNA SARS-Cov-2 vaccine rechallenge after a first episode of immune thrombocytopenic purpura.
    Chanut M; Jaidi R; Kohn M; Grange T; Brones C; Lombion N; Rousselot P; Longval T
    Platelets; 2022 May; 33(4):652-653. PubMed ID: 35225144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute immune thrombocytopenia following SARS-CoV-2 vaccination in chronic ITP patients and a healthy individual.
    Ogai A; Yoshida R; Yuasa C; Chin K; Fujimaki K; Nakajima H
    Int J Hematol; 2022 Feb; 115(2):293-295. PubMed ID: 34716890
    [No Abstract]   [Full Text] [Related]  

  • 8. Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance.
    Pavord S; Hunt BJ; Horner D; Bewley S; Karpusheff J;
    BMJ; 2021 Oct; 375():n2195. PubMed ID: 34598931
    [No Abstract]   [Full Text] [Related]  

  • 9. Immune Thrombocytopenia Following the Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine.
    Ganzel C; Ben-Chetrit E
    Isr Med Assoc J; 2021 Jun; 23(6):341. PubMed ID: 34155844
    [No Abstract]   [Full Text] [Related]  

  • 10. Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine.
    Tarawneh O; Tarawneh H
    Am J Hematol; 2021 May; 96(5):E133-E134. PubMed ID: 33476455
    [No Abstract]   [Full Text] [Related]  

  • 11. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vigilance regarding immune thrombocytopenic purpura after COVID-19 vaccine.
    Saudagar V; Patil S; Goh S; Pothiawala S
    Ir J Med Sci; 2022 Apr; 191(2):919-920. PubMed ID: 33788135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune-Mediated Thrombocytopenia Associated With Ad26.COV2.S (Janssen; Johnson & Johnson) Vaccine.
    Banerjee S; Sandhu M; Tonzi E; Tambe A; Gambhir HS
    Am J Ther; 2021 Aug; 28(5):e604-e606. PubMed ID: 34469919
    [No Abstract]   [Full Text] [Related]  

  • 14. Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH.
    Oldenburg J; Klamroth R; Langer F; Albisetti M; von Auer C; Ay C; Korte W; Scharf RE; Pötzsch B; Greinacher A
    Hamostaseologie; 2021 Jun; 41(3):184-189. PubMed ID: 33822348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of relapse after SARS-CoV-2 vaccine in the Milan cohort of thrombotic thrombocytopenic purpura patients.
    Capecchi M; De Leo P; Abbattista M; Mancini I; Agosti P; Biganzoli M; Suffritti C; Ferrari B; Lecchi A; La Marca S; Padovan L; Scalambrino E; Clerici M; Tripodi A; Artoni A; Gualtierotti R; Peyvandi F
    Haematologica; 2023 Nov; 108(11):3152-3155. PubMed ID: 36951158
    [No Abstract]   [Full Text] [Related]  

  • 16. Relapse of immune thrombotic thrombocytopenic purpura (iTTP) possibly triggered by COVID-19 vaccination and/or concurrent COVID-19 infection.
    Fang F; Tse B; Pavenski K
    BMJ Case Rep; 2022 Jul; 15(7):. PubMed ID: 35902184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination.
    Lee EJ; Cines DB; Gernsheimer T; Kessler C; Michel M; Tarantino MD; Semple JW; Arnold DM; Godeau B; Lambert MP; Bussel JB
    Am J Hematol; 2021 May; 96(5):534-537. PubMed ID: 33606296
    [No Abstract]   [Full Text] [Related]  

  • 18. VITT with inactivated SARS-CoV-2 vaccine - index case.
    Devi K; Ali N; Nasir N; Mahmood SF
    Hum Vaccin Immunother; 2022 Dec; 18(1):2036556. PubMed ID: 35254213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Temporary suspension of AstraZeneca's vaccine; a reconstruction].
    Maas DPMSM; Kramers C; Smit HJCA; Middeldorp S; Helsloot I
    Ned Tijdschr Geneeskd; 2021 Apr; 165():. PubMed ID: 33914428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of anti-SARS-CoV-2 vaccination for patients with immune thrombocytopenia.
    Crickx E; Moulis G; Ebbo M; Terriou L; Briantais A; Languille L; Limal N; Guillet S; Michel M; Mahevas M; Godeau B
    Br J Haematol; 2021 Dec; 195(5):703-705. PubMed ID: 34467525
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.